Jiangsu Gdk Biological Technology (688670.SH): Trivalent influenza vaccine receives drug registration certificate; the company may trigger a financial delisting risk warning.

Jiangsu Gdk Biological Technology (688670.SH) announced that the company recently received the Drug Registration Certificate for its split influenza virus vaccine (referred to as the "trivalent influenza vaccine") approved and issued by the National Medical Products Administration. Due to the WHO's adjustment of recommended influenza vaccine components, the trivalent influenza vaccine will become the primary product in the market this flu season. Based on the above adjustment, the company will no longer sell quadrivalent influenza vaccines this flu season and will only sell trivalent influenza vaccines. As the product has just been approved, the company currently has no trivalent influenza vaccine available for sale, and the available sales period this flu season is limited, missing the window for large-scale sales. According to the announcement, based on the company's preliminary estimates, full-year operating revenue is expected to potentially fall below 100 million yuan and the company may not achieve a turnaround. If the operating revenue for this year is below 100 million yuan and the net profit is negative, it will trigger the financial delisting risk warning criteria, and the Shanghai Stock Exchange will impose a "delisting risk warning" on the company's stock. The company's production is currently operating normally, and it is urgently advancing post-approval related work to complete product filling, packaging, and batch release as soon as possible. At the same time, it is actively carrying out market promotion efforts, making preliminary preparations for product access, bidding, and online listing, to ensure rapid sales after the product obtains batch release, striving to achieve product sales within the limited time window and minimize the adverse impact on the company's operating performance.